Compare Adaptive Biotechnologies Corp (ADPT) vs Morgan Stanley (MS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Morgan Stanley — how do they compare? Adaptive Biotechnologies Corp trades at $19.93 (market cap $3.33B), while Morgan Stanley trades at $217.22 (market cap $350.22B). The key difference: Morgan Stanley is far larger — about 105.2× Adaptive Biotechnologies Corp's market cap, and Morgan Stanley pays a 1.8% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MS | |
|---|---|---|
Market Cap | $3.33B | $350.22B |
Sector | Health | Financials |
52-Week High | $22.37 | $227.19 |
52-Week Low | $10.24 | $139.09 |
Enterprise Value | $3.19B | — |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Morgan Stanley (MS) trades at $222.10, up 3.82% today, near its consensus price target of $225.80. The stock shows strong fundamental momentum with three consecutive quarterly earnings beats and robust revenue growth, reaching $66.0B in 2025. Technical indicators are bullish, with the current price above key support levels. Recent news highlights the firm's role in leading Anthropic's IPO and expanding AI integration in wealth management.
The outlook remains positive given earnings outperformance and analyst consensus, though risks include volatile cash flows and high debt levels. Upside potential exists if the company maintains its growth trajectory and executes on strategic initiatives like the Anthropic IPO. Investors should monitor interest rate sensitivity and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
